OBM Geriatrics

Free Publication in 2017

Current issue: 2017 

Review

The Feasibility and Necessity of a Revolution in Geriatric Medicine Giacinto Libertini

Giacinto Libertini
Received: February 20, 2017; Published: April 17, 2017; doi:10.21926/obm.geriat.1702002

Editorial

OBM Geriatrics — An International Open Access Journal for 21st Century Geriatrics Medicine

Michael Fossel
Received: November 9, 2016; Published: January 6, 2017; doi:10.21926/obm.geriatr.1701001

OBM Geriatrics is an Open Access journal published quarterly online by Open BioMedical Publishing Corporation. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

OBM Geriatrics welcomes the following types of articles: original research, review, communication, opinion, case report, comment, conference report, technical note, book review, etc. There is no restriction on the length of the papers, color figures, supplementary file types. More details please see Instructions for Authors.

Register and Submit now.

Biography of the Editor-in-Chief

SuniDr. Michael Fossel obtained his PhD (Neurobiology) and his MD at Stanford University, where he had an NSF Fellowship, taught neuroanatomy, and began focusing on human aging, especially progeric syndromes.  He practiced as a Clinical Professor of Medicine at Michigan State University for almost three decades and continues to teach the Biology of Aging at the university level.

He served as the executive director of the American Aging Association and is currently the medical advisor for the Dementia Society of America. He was founding Editor-in-Chief of Rejuvenation Research. He has published more than 80 articles, chapters, and books on aging and medicine, including Cells, Aging, and Human Disease (Oxford University Press). This magisterial text, with over 4,000 references, reviews the fields of telomere biology and cell aging, and remains the only textbook on the clinical potential of telomerase. His latest book, The Telomerase Revolution, discusses prospective FDA clinical trials of telomerase therapy as an effective intervention for Alzheimer’s disease. His book was named as one of the best five science books of 2015 by the Wall Street Journal. He is president of Telocyte, a biotech firm targeting Alzheimer’s disease.